Terminated PHASE2 INTERVENTIONAL 2-arm NCT01685255

A Phase 2 Study of the IDO Inhibitor Epacadostat Versus Tamoxifen for Subjects With Biochemical-recurrent-only EOC, PPC or FTC Following Complete Remission With First-line Chemotherapy

A Randomized, Open-Label, Phase 2 Study of the IDO Inhibitor Epacadostat Versus Tamoxifen for Subjects With Biochemical-Recurrent-Only Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, or Fallopian Tube Cancer Following Complete Remission With First-Line Chemotherapy

Sponsor: Incyte Corporation

Conditions Genitourinary (GU) Tumors Ovarian Cancer

Interventions Epacadostat tamoxifen

Updated 13 times since 2017 Last updated: Mar 6, 2019 Started: Aug 31, 2012 Primary completion: Oct 23, 2014 Completion: Oct 23, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Study was terminated by the sponsor for lack of evidence of superiority and slow study accrual.

Other terminated trials from Incyte Corporation

More terminations from Incyte Corporation

Listed as NCT01685255, this PHASE2 trial focuses on Genitourinary (GU) Tumors and Ovarian Cancer and remains terminated or withdrawn. Sponsored by Incyte Corporation, it has been updated 13 times since 2012, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

13 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE2
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Apr 2022 — Jul 2024 [monthly]

Terminated PHASE2
Jan 2021 — Apr 2022 [monthly]

Terminated PHASE2

▶ Show 8 earlier versions

Apr 2019 — Jan 2021 [monthly]

Terminated PHASE2
Jun 2018 — Apr 2019 [monthly]

Terminated PHASE2
Apr 2018 — Jun 2018 [monthly]

Terminated PHASE2
Feb 2018 — Apr 2018 [monthly]

Terminated PHASE2
Aug 2017 — Feb 2018 [monthly]

Terminated PHASE2
Jul 2017 — Aug 2017 [monthly]

Terminated PHASE2

Status: Completed → Terminated
Feb 2017 — Jul 2017 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Aug 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Incyte Corporation

Data source: Incyte Corporation

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Abington, United States , Baltimore, United States , Bebington, United Kingdom , Bendigo, Australia , Bridgewater, United States , Buffalo, United States , Calgary, Canada , Cardiff, United Kingdom , Chernivtsi, Ukraine , Covington, United States and 39 more locations